The study was released by the RECOVERY group, in partnership with the University of Oxford in England. The groups put out a news release in June touting the results of the clinical trial, but full results of the trial weren’t published until July 17.
Some scientists have called dexamethasone a major breakthrough in COVID-19 treatment, as it is the first drug that has been shown to improve survival rates. Gilead’s remdesivir shortened recovery time, but didn’t reduce mortality rates.
The study, which was published in The New England Journal of Medicine, indicated a lower death rate among 2,104 patients treated with dexamethasone compared to 4,321 patients receiving usual care over a 28-day period.
The trial showed very little impact on patients who weren’t on respiratory support.
The FDA recently updated its treatment guidelines for dexamethasone, saying it can be used for up to 10 days on patients who require supplemental oxygen.
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
Growing number of polls find Americans hesitant about getting a future COVID-19 vaccine
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
